Peptides With At Least One Nonpeptide Bond Other Than A Disulfide Bond Joining Two Or More Sequences Of Amino Acid Residues, E.g., Homomeric Heterodectic Peptide Other Than Cyclic Disulfide, Depsipeptides, Etc. Patents (Class 530/323)
-
Patent number: 7569660Abstract: The present invention provides novel polypeptides comprising a prion-aggregation domain and a second domain; novel polynucleotides encoding such polypeptides; host cells transformed or transfected with such polynucleotides; and methods of making and using the foregoing.Type: GrantFiled: June 9, 2000Date of Patent: August 4, 2009Assignee: The University of ChicagoInventors: Susan Lindquist, Liming Li, Jiyan Ma, Jia-Jia Liu, Neal Sondheimer, Thomas Scheibel
-
Publication number: 20090159842Abstract: A modular linker includes an inorganic binding entity having an affinity for a substantially inorganic substance, and an organic binding entity capable of binding with an organic substance covalently bonded thereto. The modular linker is capable of being stored in a stable condition for later use. The modular linker may be synthesized by modifying the inorganic binding entity to be covalently bonded to an organic binding entity and storing the modular linker in an inert environment from about a day up to at least 1 week. The modular linker may be conjugated to an organic substance and to a substantially inorganic substance in substantially a 1:1 ratio. The modular linker may have more than one organic binding entity covalently bonded to an inorganic binding entity or vice-versa. Also, a particular modular linker may have an organic binding entity capable of binding with a nucleic acid sequence.Type: ApplicationFiled: April 25, 2007Publication date: June 25, 2009Inventors: Igor L. Medintz, Lorenzo Berti, Paolo Facci, Hedi M. Mattoussi
-
Publication number: 20090156508Abstract: The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: wherein Xaa is a D-amino acid and G is selected from the following three groups: The compounds are useful in the prophylaxis and treatment of pain, pruritis and inflammation associated with a variety of diseases and conditions.Type: ApplicationFiled: May 12, 2008Publication date: June 18, 2009Applicant: CARA THERAPEUTICS, INC.Inventors: Claudio D. Schteingart, Frederique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
-
Patent number: 7544364Abstract: Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.Type: GrantFiled: April 25, 2006Date of Patent: June 9, 2009Assignee: Theravance, Inc.Inventors: J. Kevin Judice, Jeng-Pyng Shaw, YongQi Mu, Michael W. Conner, John L. Pace
-
Publication number: 20090123531Abstract: A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.Type: ApplicationFiled: October 2, 2008Publication date: May 14, 2009Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Ae-June WANG, Chi-Heng JIAN, Shyh-Dar LI, Yi-Fong LIN, Shin-Jr LIU
-
Publication number: 20090118467Abstract: The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.Type: ApplicationFiled: October 25, 2006Publication date: May 7, 2009Applicant: Starpharma Pty LimitedInventors: Guy Yeoman Krippner, Gottfried Lichti, Pasquale Razzino, Brian Devlin Kelly, Susanne Pallich, Scott Andrew Henderson, Angela Michelle Scheppokat, Charlotte Claire Williams, Christopher John Hamilton Porter, Benjamin James Boyd, Lisa Michelle Kaminskas, Phillip Martin Rendle, Ben William Greatrex
-
Patent number: 7528105Abstract: The invention provides synthetic heparin-binding growth factor analogs having at least two different peptide growth factor analog chains, or alternatively two groups of two different peptide chains branched from branch moieties including trifunctional amino acid residues, the two groups separated by a first linker of from 3 to about 20 atoms, which peptide chain or chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: GrantFiled: February 10, 2005Date of Patent: May 5, 2009Assignees: BioSurface Engineering Technologies, Brookhaven Science AssociatesInventors: Louis A. Pena, Paul O. Zamora, Xinhua Lin, Kazuyuki Takahashi
-
Patent number: 7528104Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: May 12, 2004Date of Patent: May 5, 2009Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Publication number: 20090105149Abstract: The present invention relates to new peptide compounds capable of binding to fibroblast growth factor receptor (FGFR), said compounds comprising two individual amino acid sequences, wherein at least one of the two amino acid sequences is capable of binding to FGFR. The invention discloses the amino acid sequences of the compounds and features pharmaceutical compositions comprising thereof. Invention also relates to uses of the compounds and pharmaceutical compositions comprising thereof for the treatment or prevention of different pathological conditions, wherein FGFR plays a role in pathology and/or recovery from the disease. New peptide compounds of the invention are obtainable by the ligand presenting assembly (LPA) method.Type: ApplicationFiled: August 6, 2004Publication date: April 23, 2009Applicant: ENKAM PHARMACEUTICALS A/SInventors: Morten Albrechtsen, Elisabeth Bock, Vladimir Berezin, Arne Valdemar Holm
-
Publication number: 20090098076Abstract: The invention relates to a method of producing keratin-binding effector molecules, and to intermediates and end-products of the method according to the invention and to the use of the keratin-binding effector molecules produced according to the invention in dermocosmetics. In addition, the invention relates to a method of applying dermocosmetically active ingredients to skin and/or hair and to a method of increasing the residence time of an active ingredient on skin and hair.Type: ApplicationFiled: November 15, 2006Publication date: April 16, 2009Applicant: BASF SEInventors: Heiko Barg, Burghard Liebmann, Martin Volkert, Arne Ptock, Heike Reents
-
Publication number: 20090082254Abstract: The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications.Type: ApplicationFiled: February 13, 2007Publication date: March 26, 2009Applicant: Novo Nordisk A/SInventors: Bernd Peschke, Magali Zundel
-
Patent number: 7507790Abstract: The present invention relates to a fiber-shaping peptides that are capable of interacting with self-assembling peptides to form protein structures. The present invention also relates to methods of forming protein structures using the fiber-shaping peptides of the present invention.Type: GrantFiled: September 8, 2003Date of Patent: March 24, 2009Assignee: University of SussexInventors: Derek Woolfson, Maxim Gennadievich Ryadnov
-
Publication number: 20090062192Abstract: Dimerization of GLP-1 agonists and therapeutic uses thereof.Type: ApplicationFiled: March 20, 2006Publication date: March 5, 2009Applicant: Novo Nordisk A/SInventors: Leif Christensen, Jesper Lau, Jane Spetzler, Thomas Kruse Hansen
-
Publication number: 20090048147Abstract: The present invention relates to a compound comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The linker moiety is between the peptide moiety and the water-soluble polymer moiety. In certain embodiments, the linker moiety has the structure: wherein ?, ?, and ? are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein ?, ?, and ? are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein ?, ?, ?, and ? are each integers whose values are independently selected. Alternatively, the linker structure may have the following structure: wherein ? and ? are each integers whose values are independently selected.Type: ApplicationFiled: January 30, 2008Publication date: February 19, 2009Applicant: Affymax, Inc.Inventors: Christopher P. Holmes, Anjan Chakrabarti, Brian T. Frederick, Yijun Pan, Yaohua S. Dong, Ashok Bhandari
-
Publication number: 20090048166Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: July 11, 2008Publication date: February 19, 2009Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Publication number: 20090042235Abstract: The present invention provides a method of photoregulating the formation of a peptide-protein complex by using a novel peptide in which a structural change for recognizing a protein is photoregulated, in the formation of a complex between a peptide capable of recognizing a protein and a protein of interest. A peptide having an intramolecular cross-linkage via a photocleavable cross-linking group, and method for producing the same. Further, a peptide which has an intramolecular cross-linkage via a photocleavable cross-linking group and forms a cyclic structure together with the cross-linking group, containing a peptide having an epitope corresponding to a functional protein or a ligand at a part which forms the cyclic structure, and method for producing the same.Type: ApplicationFiled: August 14, 2006Publication date: February 12, 2009Inventors: Shun Hirota, Yuji Hamazaki
-
Publication number: 20090011986Abstract: The present invention relates to compounds of the Formula (I), wherein X1 and X2 independently represent O, NH or S; R1 and R2 are independently selected from the group consisting of a C1-C30 hydrocarbyl group, an amino acid bonded via an amide bond or a peptide bonded via an amide bond each having up to 200 amino acids, the conjugated residue X1 or X2 in this case being NH, and hydrogen, both radicals R1 and R2 preferably not being H; and R3 is a residue selected from group consisting of —S—R6, wherein R6 is a C1-C30 hydrocarbyl group, at least one of R1 and R2 not being H when X1 and X2 are oxygen, —S—CH2—CH(NH2)(COOH) (cysteine-S-yl), a homologue or derivative (e.g.Type: ApplicationFiled: May 3, 2006Publication date: January 8, 2009Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel, Jitka Ulrichova, Thomas J. Schmidt
-
Publication number: 20080312159Abstract: Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.Type: ApplicationFiled: May 22, 2008Publication date: December 18, 2008Inventors: Neville Robert Kallenbach, Anne W. Young, Zhigang Liu, Chunhui Zhou
-
Patent number: 7446094Abstract: Compounds of general formula (I) wherein R1, R2, R3 are as defined and R4 groups are each independently selected from NR2, O and S; are of use in treatment of cancers.Type: GrantFiled: June 23, 2004Date of Patent: November 4, 2008Assignee: Instituto Biomar S.A.Inventors: Paco Romero, Leyre Malet, Librada Maria Cañedo, Carmen Cuevas, José Fernando Reyes
-
Patent number: 7446099Abstract: Complexes are disclosed which are a combination of a polynucleotide and a biodegradable polyacetal-peptide. The disclosed complexes are useful for cell transfection.Type: GrantFiled: February 27, 2004Date of Patent: November 4, 2008Assignee: Nitto Denko CorporationInventors: Sang Van, Nitnara Viroonchatapan, Shouping Ji, Kenji Matsumoto, Lei Yu
-
Publication number: 20080248044Abstract: Polyepitopic peptides of E6 and E7 proteins of Human Papillomavirus, their production, and methods of treating pathologies in which a polyepitopic peptide of the E6 and E7 protein of Human Papillomavirus is recognized by the cellular immune system.Type: ApplicationFiled: September 21, 2007Publication date: October 9, 2008Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM, PEPTIDE IMMUNE LIGANDSInventors: Jeannine Choppin, Isabelle Bourgault Villada, Jean-Gerard Guillet, Francine Connan, Estelle Ferries
-
Patent number: 7429639Abstract: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.Type: GrantFiled: September 9, 2004Date of Patent: September 30, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Maha Ayyoub, Danila Valmori
-
Publication number: 20080234464Abstract: An object of the present invention is to provide a compound with a structure wherein amino acid or oligopeptide side chains are bonded to a main chain. The present invention provides a compound represented by the following formula (1). wherein n1 to n3, and m1 to m6 are certain integers; Y is a hydroxyl or an amino group; E is N or CH; R is an amino acid residue, or a peptide residue consisting of 2 to 100 amino acid residues; and L is a hydrogen atom, a group containing a lipid group, a group containing a fatty acid residue, or a group containing a fluorescent group.Type: ApplicationFiled: April 21, 2006Publication date: September 25, 2008Inventors: Hisafumi Ikeda, Madoka Tonosaki
-
Patent number: 7427590Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.Type: GrantFiled: September 12, 2002Date of Patent: September 23, 2008Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Ramot at Tel-Aviv University, Ltd.Inventors: Douglas E. Brenneman, Raquel Castellon, Catherine Y. Spong, Janet M. Hauser, Illana Gozes
-
Publication number: 20080221303Abstract: The present invention relates to the synthesis of peptide-oligonucleotide conjugates (POC). More specifically, the invention relates to a novel method for the preparation of peptide-oligonucleotide conjugates, which can be conducted under mild conditions on solid support, can be performed manually or by a synthesizer, can be used to synthesize alternating sequences of peptides and oligonucleotides, and is applicable to the synthesis of a wide variety of peptide-oligonucleotide conjugates constructed from alternate peptide and oligonucleotide blocks.Type: ApplicationFiled: February 17, 2005Publication date: September 11, 2008Inventors: Jehoshua Katzhendler, Yakir Klauzner, Irena Beylis, Michael Mizhiritskii, Yaacov Shpernat, Boris Ashkenazi, Dmitri Fridland
-
Patent number: 7423020Abstract: This invention relates to the use of an agent that modulates the interaction between a SMR1 peptide and a metal-lopeptidase for the preparation of a medicament for preventing or treating a Central Nervous System disorder giving rise to a mental disorder.Type: GrantFiled: December 24, 2001Date of Patent: September 9, 2008Assignees: Institut Pasteur, Centre National de la Recherche Scientifique (C.N.R.S)Inventors: Catherine Rougeot, Francois Rougeon
-
Publication number: 20080207485Abstract: The invention discloses MHC oligomers and methods for making the same comprising at least two functional MHC complexes having a peptide binding groove, each MHC complex having a peptide bound in the peptide binding groove of the MHC complex, wherein each peptide has a modification which allows highly specific oligomersation of the functional MHC complexes through a core structure.Type: ApplicationFiled: February 1, 2006Publication date: August 28, 2008Inventor: Nikolai Franz Gregor Schwabe
-
Patent number: 7414105Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: GrantFiled: October 27, 2005Date of Patent: August 19, 2008Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Guy Lalonde, Peter J. Schatz, David Tumelty, Balu Palani, Genet Zemede
-
Patent number: 7408026Abstract: Proteins of moderate size having native peptide backbones are produced by a method of native chemical ligation. Native chemical ligation employs a chemoselective reaction of two unprotected peptide segments to produce a transient thioester-linked intermediate. The transient thioester-linked intermediate then spontaneously undergoes a rearrangement to provide the full length ligation product having a native peptide bond at the ligation site. Full length ligation products are chemically identical to proteins produced by cell free synthesis. Full length ligation products may be refolded and/or oxidized, as allowed, to form native disulfide-containing protein molecules. The technique of native chemical ligation is employable for chemically synthesizing full length proteins.Type: GrantFiled: November 8, 2000Date of Patent: August 5, 2008Assignee: The Scripps Research InstituteInventors: Stephen B. H. Kent, Tom W. Muir, Philip E. Dawson
-
Publication number: 20080182785Abstract: Novel protracted GLP-1 compounds and therapeutic uses thereof.Type: ApplicationFiled: October 7, 2005Publication date: July 31, 2008Applicant: Novo Nordisk A/SInventors: Jesper Lau, Thomas Kruse Hansen
-
Patent number: 7402556Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.Type: GrantFiled: August 23, 2001Date of Patent: July 22, 2008Assignee: Medarex, Inc.Inventors: André Trouet, Vincent Dubois, Alexandre Passioukov
-
Publication number: 20080161537Abstract: Provided herein are methods for introducing fluorine atom onto a biomolecule comprising: (i) providing a linker comprising a thiol-reactive terminus and an azido/alkyne-reactive terminus; (ii) reacting the thiol-reactive terminus of the linker with a biomolecule comprising at least one thiol group or a reactive derivative thereof; and (iii) subsequently reacting the azido/alkyne-reactive terminus of the linker with a fluorine-substituted azide or alkyne respectively. Also provided are compositions and method of synthesis of bifunctional linkers and bioconjugates as well as radio-diagnostic agents comprising fluorine-labeled biomolecules.Type: ApplicationFiled: December 20, 2007Publication date: July 3, 2008Applicant: GENERAL ELECTRIC COMPANYInventors: Omayra Liz Padilla De Jesus, Ernest William Kovacs, Matthias Eberhard Glaser, Erik Arstad, Faisal Ahmed Syud
-
Publication number: 20080153082Abstract: This invention provides polyanionic polymer conjugates containing non-nucleotide polyanionic polymers that are useful in detecting target analytes such as proteins or small molecules. The invention also provides nanoparticles bound to polyanionic polymer conjugates and methods of preparation and use thereof. The polyanionic polymer conjugates have the formula: L-O—[PO2—O-Z-O]n—PO2—O—X wherein n ranges from 1 to 200; L represents a moiety comprising a functional group for attaching the polyanion polymer to the nanoparticle surface; Z represents a bridging group, and X represents Q, X? or -Q-X?, wherein Q represents a functional group for attaching a recognition probe to the polyanion polymer, and X? represents a recognition probe.Type: ApplicationFiled: August 6, 2007Publication date: June 26, 2008Applicant: Nanosphere, Inc.Inventors: James J. Storhoff, Robert L. Letsinger, Susan R. Hagenow
-
Publication number: 20080152588Abstract: Metal chelators of formula (I) and formula (II) are disclosed or a farmaceutically acceptable salt thereof. Also disclosed are metal chelator-targeting moiety complexes, metal chelator-targeting moiety-metal conjugates, kits, and methods of their preparation and use in diagnosis and/or treatment of diseases and conditions, including, inter alia, cancer and thrombosis.Type: ApplicationFiled: August 9, 2005Publication date: June 26, 2008Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ASInventors: Martin Wade Brechbiel, Thomas Clifford
-
Publication number: 20080139670Abstract: (A compound comprises a thiopeptide, or derivative or analogue thereof, the thiopeptide comprising a C-terminal carboxylic acid group, and a functional group for attachment to a drug, characterised in that the compound is adapted to carry or transport a drug.Type: ApplicationFiled: January 17, 2005Publication date: June 12, 2008Applicant: THE UNIVERSITY OF MANCHESTERInventor: Patrick Dawson Bailey
-
Patent number: 7378485Abstract: A novel class of compounds, known as peptide nucleic acids, bind complementary ssDNA and RNA strands more strongly than a corresponding DNA. The peptide nucleic acids generally comprise ligands such as naturally occurring DNA bases attached to a peptide backbone through a suitable linker.Type: GrantFiled: May 23, 2002Date of Patent: May 27, 2008Inventors: Ole Buchardt, Michael Egholm, Peter Eigil Nielsen, Rolf Henrik Berg
-
Patent number: 7368528Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO-A-B-D-E-(G)s-K I wherein R1, R2, X, A, B, D, E, G, K, and s have the meanings stated in the description. The compounds have antineoplastic activity.Type: GrantFiled: July 11, 2005Date of Patent: May 6, 2008Assignee: Abbott GmbH & Co. KGInventors: Wilhelm Amberg, Teresa Barlozzari, Harald Bernard, Ernst Buschmann, Andreas Haupt, Hans-Guenther Hege, Bernd Janssen, Andreas Kling, Helmut Lietz, Kurt Ritter, Martina Ullrich, Jurgen Weyman, Thomas Zierke
-
Patent number: 7348010Abstract: The present invention relates to peptides of the extracellular domain of a HER-2/neu protein, conjugates comprising said peptides linked to an immunogenic carrier, compositions thereof, nucleic acid molecules, vectors and transformed or transfected host cells comprising said nucleic acid molecules encoding said peptides or conjugates, and methods for producing the disclosed peptides, conjugates and compositions. The present invention also relates to diagnostic methods of detecting cancerous conditions associated with HER-2/neu or monitoring the effectiveness of treatment against cancerous conditions associated with HER-2/neu. The present invention also relates to methods of eliciting or enhancing an immune response to HER-2/neu in a subject in need thereof.Type: GrantFiled: February 27, 2002Date of Patent: March 25, 2008Inventors: Christoph Zielinski, Otto Scheiner, Erika Jensen-Jarolim, Heimo Breiteneder, Hubert Pehamberger
-
Patent number: 7348310Abstract: The invention relates to aplidine derivatives of the general formula: which are useful for the treatment of tumors.Type: GrantFiled: July 2, 2001Date of Patent: March 25, 2008Assignee: Pharma Mar, S.A.Inventors: Ignacio Rodriguez, Concepción Polanco, Felix Cuevas, Paloma Mendez, Carmen Cuevas, Pilar Gallego, Simon Munt, Ignacio Manzanares
-
Patent number: 7345020Abstract: The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C—C? loop of the D1 domain; residues 317-323, the C—C? loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.Type: GrantFiled: May 7, 2004Date of Patent: March 18, 2008Assignee: Thomas Jefferson UniversityInventors: Robert Korngold, Ziwei Huang
-
Publication number: 20080058269Abstract: The present invention relates to peptides, or fragments thereof, isolated from the skin secretions of amphibians and which act as stimulators of insulin secretion and pancreatic beta cell function. The invention also encompasses peptide having at least 80%, preferably at least 85%, more preferably at least 90%, optionally more than 95%, sequence identity based on the ClustalW alignment method with the respective amino acid sequences of SEQ ID Nos. 1 to 17. Furthermore, the invention also includes peptides selected from the group comprising brevinins, dermaseptins and esculentins for stimulating insulin secretion by activation of physiological stimulus-secretion coupling pathways. These peptides are useful to stimulate insulin secretion and/or moderate blood glucose excursions. These peptides may be used for treatment of type 1 or type 2 diabetes mellitus.Type: ApplicationFiled: November 17, 2004Publication date: March 6, 2008Applicant: UNVERSITY OF ULSTERInventors: Yassar Hassan Atef Abdel-Wahab, Lamin Marenah, David Francis Orr, Stephen McClean, Peter Raymond Flatt, Chris Shaw
-
Publication number: 20080026990Abstract: The invention relates to cyclic depsipeptides, especially 18-membered cyclohexadepsipeptides of general formula (I) and the salts thereof, wherein R1 represents nitrobenzyl or R?R?N-benzyl—wherein R? and R? independently represent hydrogen, optionally substituted C1-C4-alkyl, formyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxycarbonyl, or hydroxy-C1-C2-alkyl-sulfonyl-C1-C2-alkyl, or, together with the nitrogen atom to which they are bound, R? and R? form an optionally substituted monocyclic or polycyclic, optionally bridged and/or spirocyclic, saturated or unsaturated heterocycle containing between one and three other heteroatoms from the group of nitrogen, oxygen and sulphur, or R? and R? together form C3-C5-alkylene monocarbonyl or an optionally susbtituted diacyl radical of a C4-C6-dicarboxylic acid—and R2, R3 and R4 independently represent C1-C4-alkyl.Type: ApplicationFiled: December 7, 2004Publication date: January 31, 2008Applicant: BAYER HEALTHCARE AGInventors: Peter Jeschke, Achim Harder
-
Patent number: 7312190Abstract: The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.Type: GrantFiled: March 15, 2004Date of Patent: December 25, 2007Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
-
Patent number: 7273920Abstract: The invention relates to novel compounds comprising a ubiquitination recognition element and a protein binding element. The invention also relates to the use of said compounds for modulating the level and/or activity of a target protein. The compounds are useful for the treatment of disease such as infections, inflammatory conditions, cancer and genetic diseases. The compounds are also useful as insecticides and herbicides.Type: GrantFiled: January 16, 2003Date of Patent: September 25, 2007Assignee: Wellstat BioCatalysis, LLCInventors: John H. Kenten, Steven F. Roberts
-
Patent number: 7273615Abstract: The present invention provides a cell-free protein synthesis method characterized by a cell-free protein synthesis reaction solution that is weakly reducing and suitable for protein folding, performing a weakly reducing synthesis reaction, and preferably performing a translation reaction with the further addition of a substance catalyzing a disulfide bond exchange reaction at the beginning of the translation reaction. This method allows for proper formation of intramolecular disulfide bonds in the protein and efficiently provides protein having substantially the same function as the original protein. Specifically, it provides antibody protein that binds specifically to an antigen.Type: GrantFiled: February 28, 2003Date of Patent: September 25, 2007Assignee: CellFree Sciences Co., Ltd.Inventors: Yaeta Endo, Takayasu Kawasaki, Tatsuya Sawasaki
-
Patent number: 7256043Abstract: The invention provides a peptide having at least 3 amino acids comprising an amino acid sequence selected from a) X1SM [SEQ.ID.NO.:1] b) LX2HK [SEQ.ID.NO.:2] c) PSGX3ARA [SEQ.ID.NO.:9] d) SX4RSMNF [SEQ.ID. NO.:16] e) LX5HKSMP [SEQ.ID.NO.:18] in which X is a basic amino acid residue, X1 is Q or P, X2 is A or T, X3 is an acidic amino acid residue and X4 is P or Q, the invention further provides non-viral cell-targeting vector complexes and methods associated therewith.Type: GrantFiled: March 14, 2002Date of Patent: August 14, 2007Assignee: ICH Productions LimitedInventors: Stephen Lewis Hart, Michele Writer
-
Patent number: 7252827Abstract: Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). Also disclosed are immunogenic compositions comprising a pharmaceutically acceptable carrier and the fusion protein.Type: GrantFiled: March 25, 1997Date of Patent: August 7, 2007Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Amy J. Weiner, Michael Houghton
-
Patent number: 7244704Abstract: Compositions and methods of using compositions with a nuclear targeting peptide containing a nonclassical nuclear localization signal to deliver selected molecules to the nucleus of eukaryotic cells are provided. The compositions are particularly useful in gene transfer methods.Type: GrantFiled: February 16, 2005Date of Patent: July 17, 2007Assignee: Trustees of the University of PennsylvaniaInventor: Scott L. Diamond
-
Patent number: 7223833Abstract: A novel class of peptide nucleic acids are described which include a conjugate attached thereto. The peptide nucleic acids generally comprise ligands such as naturally occurring DNA bases attached to a peptide backbone through a suitable linker.Type: GrantFiled: October 6, 1994Date of Patent: May 29, 2007Assignees: Isis Pharmaceuticals, Inc.Inventors: Peter Nielsen, Ole Buchardt, Soren Holst Sonnechsen, Jesper Lohse, Michael Egholm, Muthiah Manoharan, John Kiely, Michael Griffith, Kelly Sprankle
-
Patent number: 7205273Abstract: The present invention relates to liposomes and virosomes and, more particularly, to liposomal and virosomal delivery systems for transporting materials such as drugs, nucleic acids and proteins.Type: GrantFiled: June 5, 2002Date of Patent: April 17, 2007Assignee: The University of British ColumbiaInventors: Pieter R. Cullis, Lewis S. L. Choi, Myrna Monck, Austin Bailey